Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Exclusion Criteria22

• Pregnant or lactating women;
• The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;
• Diffuse liver cancer;
• Patients with autoimmune diseases, organ / hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);
• Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;
• Patients who have participated in other clinical trials in the recent three months;
• Previous history of other malignancies or have received targeted therapy and other PD-1 / PD-L1 inhibitor therapy;
• Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;
• Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose\> 10mg / day prednisone or other efficacy hormones);
• Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment；
• esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment；
• Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count \<50109 / L and severe coagulation abnormalities against surgery (anticoagulation therapy and / or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);
• A stubborn amount of ascites, pleural fluid, malignant fluid;
• Active infection, especially the inflammation of the biliary tract system;
• Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;
• Previously allergic to PD-1 / PD-L1 mAb / any component of the targeted drug or other similar trials;
• Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg);
• Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) \<50%;
• Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of\> 1.0g);
• Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;
• According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;
• Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.